Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.47154
Abstract: This cohort study investigates the association of hormone receptor status and first-line endocrine therapy with survival among patients with hormone receptor–positive (HR+) and human epidermal growth factor receptor 2–positive (ERBB2+ metastatic breast cancer. read more here.
Keywords: erbb2 metastatic; survival; breast cancer; metastatic breast ... See more keywords